Journal
BIOCHEMISTRY
Volume 52, Issue 20, Pages 3532-3542Publisher
AMER CHEMICAL SOC
DOI: 10.1021/bi301705c
Keywords
-
Categories
Funding
- RIKEN
- Ministry of Education, Science, Sports, Culture and Technology of Japan (MEXT)
- Canadian Institutes of Health Research (CIHR) [MOP-84523]
- Natural Sciences and Engineering Research Council of Canada (NSERC)
- Michael Smith Foundation for Health Research (MSFHR)
- Grants-in-Aid for Scientific Research [23760758, 23680039, 24570143] Funding Source: KAKEN
Ask authors/readers for more resources
Amyloid-beta (A beta) peptides represent key players in the pathogenesis of Alzheimer's disease (AD), and mounting evidence indicates that soluble A beta oligomers mediate the toxicity. Prefoldin (PFD) is a molecular chaperone that prevents aggregation of misfolded proteins. Here we investigated the role of PFD in M aggregation. First, we demonstrated that PFD is expressed in mouse brain by Western blotting and immunohistochemistry and found that PFD is upregulated in AD model APP23 transgenic mice. Then we investigated the effect of recombinant human PFD (hPFD) on A beta(1-42) aggregation in vitro and found that hPFD inhibited Afi fibrillation and induced formation of soluble Afi oligomers. Interestingly, cell viability measurements using the 3-(4,5-dirnethyldnazol-2-y1)-2,5-diphenyltetrazoliurn bromide assay showed that A beta oligomers formed by hPFD were 30-40% less toxic to cultured rat pheochromocytoma (PC 12) cells or primary cortical neurons from embryonic CS7BL/6CrSlc mice than previously reported A beta oligomers (formed by archaeal PFD) and A beta fibrils (p < 0.001). Thioflavin T measurements and immunoblotting indicated different structural properties for the different A beta oligomers. Our findings show a relation between cytotoxicity of A beta ofigomers and structure and suggest a possible protective role of PFD in AD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available